TxCell

Last News

January, 2010 : TxCell appoints Miguel Forte Chief Medical Officer

July, 2009
: The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.

May 5, 2009 : TxCell opened a new center of investigation for its Phase I/IIa clinical trial.

 More News


Events

Events

January 25-27, 2010
Phacilitate Cell & Gene Therapy Forum 2010
The Grand Hyatt,Washington, US
More information
here


More Events

Home Page
Home

New approach in immunosuppressive strategies

Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system.

Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity.

TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage).

TxCell is a spin-off from the French Medical Research Institute (INSERM) .

 

Spot Light

TxCell Science Video Click to Enlarge

A new TxCell publication
released in 2009

Learn More





Copyright Txcell SA © 2008 - 2009 - All Rights Reserved - Legal Notice & Privacy Policy